Avidity Biosciences

54 articles with Avidity Biosciences

• Avidity Biosciences Reports Third Quarter 2021 Financial Results and Recent Highlights

  11/9/2021

  Avidity Biosciences, Inc. (Nasdaq: RNA), today reported financial results for the third quarter and nine months ended September 30, 2021 and highlighted recent corporate progress.

• 

  Clinical Catch-Up: November 1-5

  11/8/2021

  The first week of November was marked by numerous clinical trial announcements. Here’s a look.

• Avidity Announces First Person Dosed with an Antibody Oligonucleotide Conjugate (AOC™)

  11/4/2021

  Avidity Biosciences, Inc., a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide Conjugates, announced that the first participants in the Phase 1/2 MARINA trial have been dosed with Avidity's lead AOC product candidate, AOC 1001, marking the first time a person has been dosed with an AOC.

• Avidity Biosciences to Participate in Upcoming Investor Conferences - Nov 02, 2021

  11/2/2021

  Avidity Biosciences, Inc. a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide Conjugates, announced that the Avidity management team will be participating at the following conferences.

• FDA Grants Fast Track Designation to AOC 1001 for the Treatment of Myotonic Dystrophy Type 1

  10/18/2021

  Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide Conjugates (AOCs™), today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track Designation to its lead program, AOC 1001, for the treatment of myotonic dystrophy type 1 (DM1).

• Avidity Biosciences to Participate in Upcoming Investor Conferences - Aug 31, 2021

  8/31/2021

  Avidity Biosciences, Inc. a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide Conjugates, announced that the Avidity management team will be participating at the following conferences

• European Medicines Agency (EMA) Grants Orphan Designation for AOC 1001

  8/24/2021

  Avidity Biosciences, Inc., a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide Conjugates, announced that the European Commission has granted orphan designation for AOC 1001.

• Avidity Biosciences Enters Into Collaboration with FSHD Clinical Trial Network to Support Development of Biomarkers for Future Clinical Trial Use

  8/16/2021

  Avidity Biosciences, Inc. today announced its collaboration with the Facioscapulohumeral Muscular Dystrophy (FSHD) Clinical Trial Research Network (FSHD CTRN) to support a natural history study for people living with FSHD called the Motor Outcomes to Validate Evaluations Plus (MOVE+) Study.

• Avidity Biosciences Reports Second Quarter 2021 Financial Results and Recent Highlights

  8/9/2021

  Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide Conjugates (AOCs™), today reported financial results for the second quarter and six months ended June 30, 2021 and highlighted recent corporate progress.

• Avidity Biosciences, Inc. Announces Pricing of Public Offering of Common Stock

  8/3/2021

  Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide Conjugates (AOCs™), today announced the pricing of an underwritten public offering of 8,000,000 shares of its common stock at a price to the public of $18.00 per share.

• Avidity Biosciences, Inc. Announces Proposed Public Offering of Common Stock - Aug 02, 2021

  8/2/2021

  Avidity Biosciences, Inc., a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide Conjugates, announced that it intends to offer and sell, subject to market and other conditions, $100 million of shares of its common stock in an underwritten public offering.

• Avidity Biosciences Receives IND Clearance from FDA to Proceed with the Phase 1/2 MARINA™ Trial of AOC 1001 in Adults with Myotonic Dystrophy (DM1)

  8/2/2021

  Avidity Biosciences, Inc. today announced that the U.S. Food and Drug Administration (FDA) cleared the company to proceed with the Phase 1/2 MARINA™ clinical trial of AOC 1001 in adults with myotonic dystrophy type 1 (DM1).

• Avidity Biosciences Announces Updates on the Pipeline and Platform at Virtual Investor and Analyst Event

  5/19/2021

  AOC 1001 demonstrated favorable safety profile in GLP toxicology studies - remains on track to initiate clinical studies in 2H 2021 AOC 1044 named as the clinical development candidate for DMD Avidity to live video webcast investor and analyst event today at 8:00 am PT / 11:00 am ET

• Avidity Biosciences Reports First Quarter 2021 Financial Results and Recent Highlights

  5/12/2021

  Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company pioneering a new class of oligonucleotide-based therapies called Antibody Oligonucleotide Conjugates (AOCs™), today reported financial results for the first quarter ended March 31, 2021 and highlighted recent corporate progress.       

• 

  Lilly Intensifies RNA-Focused Drug Development with MiNA Therapeutics' saRNA Platform

  5/11/2021

  Eli Lilly announced a drug development collaboration with MiNA Therapeutics Limited focusing on five novel drug candidates that could be worth up to $245 million.

• Avidity Biosciences to Host Virtual Investor and Analyst Event on May 19, 2021

  5/3/2021

  Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company pioneering a new class of oligonucleotide-based therapies called Antibody Oligonucleotide Conjugates (AOCs™), today announced that it will host a virtual investor and analyst event focused on the company's AOC platform on Wednesday, May 19, 2021, from 8:00 a.m. to 10:00 a.m. PT/11:00 a.m. to 1:00 p.m. ET.

• Avidity Biosciences to Present Oral Presentation on AOC 1001 for DM1 at American Academy of Neurology (AAN) 2021 Virtual Annual Meeting

  4/16/2021

  Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company pioneering a new class of oligonucleotide-based therapies called Antibody Oligonucleotide Conjugates (AOCs™), today announced that preclinical data for their lead candidate, AOC 1001 in development for myotonic dystrophy type 1 (DM1), will be presented at the American Academy of Neurology (AAN) 2021 Virtual Annual Meeting

• Avidity Biosciences to Participate in Upcoming Investor Conferences

  3/25/2021

  Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company pioneering a new class of oligonucleotide-based therapies called Antibody Oligonucleotide Conjugates (AOCs ™ ), today announced that management will be participating in the following virtual investor conferences: Guggenheim Healthcare Talks—Genomic Medicines

• Avidity Biosciences Reports Fourth Quarter and Year-End 2020 Financial Results and Recent Highlights

  3/15/2021

  Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company pioneering a new class of oligonucleotide-based therapies called Antibody Oligonucleotide Conjugates (AOCs™), today reported financial results for the fourth quarter and year ended December 31, 2020 and highlighted recent corporate progress.       

• 

  BioSpace Movers & Shakers, Feb. 19

  2/19/2021

  Biopharma and life sciences companies strengthen their leadership teams and boards with these Movers & Shakers.